{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:43:16Z","timestamp":1785519796478,"version":"3.56.0"},"reference-count":18,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2013,6,6]]},"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We used data from two randomised trials of AZD0865 25\u201375\u2005mg\/day versus esomeprazole 20 or 40\u2005mg\/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of &gt;0.5 in mean QOLRAD scores was seen with regurgitation \u22654\u2005days\/week versus &lt;4\u2005days\/week. The prevalence of frequent, persistent regurgitation (\u22654\u2005days\/week) at week 4 among heartburn responders (\u22641\u2005day\/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial numbers<\/jats:title>\n                  <jats:p>NCT00206284 and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00206245\">NCT00206245<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2013-304883","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T20:26:08Z","timestamp":1373055968000},"page":"720-726","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy"],"prefix":"10.1136","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct00206245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00206284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00206245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00206284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00206245","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Peter J","family":"Kahrilas","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jonsson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Denison","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rje","family":"Wernersson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesta","family":"Hughes","sequence":"additional","affiliation":[{"name":"Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,7,5]]},"reference":[{"key":"2025090723375381000_63.5.720.1","doi-asserted-by":"crossref","unstructured":"van Pinxteren B Sigterman KE Bonis P . Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010;11:CD002095.","DOI":"10.1002\/14651858.CD002095.pub4"},{"key":"2025090723375381000_63.5.720.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04406.x"},{"key":"2025090723375381000_63.5.720.3","doi-asserted-by":"crossref","unstructured":"Donnellan C Sharma N Preston C . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;(2):CD003245.","DOI":"10.1002\/14651858.CD003245.pub2"},{"key":"2025090723375381000_63.5.720.4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.146"},{"key":"2025090723375381000_63.5.720.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.022"},{"key":"2025090723375381000_63.5.720.6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.197"},{"key":"2025090723375381000_63.5.720.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"2025090723375381000_63.5.720.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01544.x"},{"key":"2025090723375381000_63.5.720.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.08.014"},{"key":"2025090723375381000_63.5.720.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03451.x"},{"key":"2025090723375381000_63.5.720.11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.200063"},{"key":"2025090723375381000_63.5.720.12","first-page":"41","article-title":"Quality of life in reflux and dyspepsia patients. psychometric documentation of a new disease-specific questionnaire (QOLRAD)","volume":"583","author":"Wiklund","year":"1998","journal-title":"Eur J Surg Suppl"},{"key":"2025090723375381000_63.5.720.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03932.x"},{"key":"2025090723375381000_63.5.720.14","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-85"},{"key":"2025090723375381000_63.5.720.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04142.x"},{"key":"2025090723375381000_63.5.720.16","unstructured":"Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, USA: Food and Drug Administration, 8 December 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf (accessed 29 Jan 2013)."},{"key":"2025090723375381000_63.5.720.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03281.x"},{"key":"2025090723375381000_63.5.720.18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.7.707"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2013-304883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:37:58Z","timestamp":1757313478000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2013-304883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,5]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,4,7]]},"published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1136\/gutjnl-2013-304883"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2013-304883","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,5]]}}}